JAGUAR HEALTH, INC. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
JAGUAR HEALTH, INC. (JAGX) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $5.64 million for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-15.
Discontinued › Notes › Income Taxes
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2017-02-15
- JAGUAR HEALTH, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2016 was $5.64M, a 17.81% increase from fiscal 2015.
- JAGUAR HEALTH, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2015 was $4.78M, a 42.57% increase from fiscal 2014.
- JAGUAR HEALTH, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2014 was $3.36M.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2016-12-31 | $5.64M 10-K · filed 2017-02-15 |
| 2015-12-31 | $4.78M 10-K · filed 2017-02-15 |
| 2014-12-31 | $3.36M 10-K · filed 2016-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |